Azelis to Distribute Angus’ Portfolio of Nitroalkanes in Europe

Angus Chemical Company announced an arrangement with Azelis as part of its new distribution strategy for the company’s complete portfolio of nitroalkanes and their derivatives sold in Europe. The Belgian specialty chemicals distributor has been appointed as a distribution partner, effective Jan. 1, 2017. The partnership includes the biotechnology market on a pan-European basis (including Turkey, and excluding Finland, Lithuania, Latvia and Estonia until April 1, 2017) and paints, coatings and other industrial markets for France, Belgium, The Netherlands and Luxembourg.

“We look forward to the technical expertise and logistics capabilities the Azelis team brings to delivering the products and support our Life Sciences customers need on a pan-European basis, while providing a more focused geographical approach for customers in specific paints and coatings, and other industrial markets,” said Liam Doherty, business vice president, EMEA and India.

Matthew Dickman, Azelis’ market segment director Pharma, added: “Angus and Azelis Pharma share the same focus on delivering market-specific solutions and expertise. The partnership will enable both parties to focus on providing the highest level of technical, logistical and customer service support to the growing customer base across Europe and Turkey. We are delighted to partner with Angus for this strategic business, utilising the extensive network of Azelis and the unrivalled technical and product experience of Angus to drive growth and innovation for our customers.”

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
19.03.2025 • TopicsStrategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.

Photo
19.03.2025 • TopicsStrategy

The Future of Demand for Chemicals

The chemical industry is shifting to sustainability-related products, with demand growing 4.5 times faster than conventional ones. Companies must revise their market strategies to capitalize on this opportunity.